[1] 张智海,张智若,刘忠厚,等.中国大陆地区以-2.0SD为诊断标准的骨质疏松症发病率回顾性研究[J].中国骨质疏松杂志, 2016, 22(1): 1-8.[2] 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2017) [J].中国全科医学,2017,3(20):3963-3982. [3] 贾英民,李瑞玉,武密山,等,补肾方药有效成分不同比例配伍对成骨细胞增殖和分化的影响[J].中国组织工程研究,2015,19(24): 3773-3777.[4] 万雷,黄宏兴,罗明,等.Wnt/β-catenin信号通路拮抗剂与骨质疏松[J].辽宁中医药大学学报,2014,16(12):73-75.[5] Simpson CA,Foer D,Lee GS,et al.Serum levels of sclerostin, Dickkopf-1, and secreted frizzled-related protein-4 are not changed in individuals with high bone mass causing mutations in LRP5.Osteoporos Int.2014;25(10): 2383-2388.[6] Ke HZ,Richards WG,Li X,et al.Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases.Endocr Rev.2012;33(5): 747-783.[7] 许兵,金红婷,王萧枫,等.补肾活血含药血清对成骨细胞经典Wnt/β-catenin 通路的影响研究[J].中国骨伤2015,28(6):553-558.[8] 彭昕,曾锦宁,张叔琦,等.壮骨止痛方对体外培养成骨细胞Wnt/β-catenin信号通路的影响[J].中国中西医结合杂志,2017,37(09): 1105-1108. [9] 黄宏兴,吴青,李跃华,等.肌肉、骨骼与骨质疏松专家共识[J].中国骨质疏松杂志,2016,22 (10):1221-1229.[10] 万雷,黄宏兴,蔡桦,等.补肾健脾活血方对老年女性骨质疏松患者疼痛和血清β-CTx、N-MID、T-PINP的影响[J]. 辽宁中医杂志, 2015,42(9):1690-1692.[11] 万雷,黄宏兴,刘庆思,等.骨康对绝经后骨质疏松症患者骨密度、血清E2、SOD、MDA的影响[J].医药前沿,2012,2(14):93-94.[12] 王凡,黄宏兴,王吉利,等. 补肾健脾活血方干预过表达DKK1骨细胞对细胞活性及BMP2的影响[J].中国骨质疏松杂志,2017,23(6): 711-714,718. [13] 万雷,黄宏兴,黄红,等.过表达DKK1、Sost重组腺病毒载体的构建及其对MG63细胞和相关蛋白的影响[J].广州中医药大学学报, 2016,(4):578-584.[14] Balemans W,Van Hul W.Human genetics of SOST.J Musculoskelet Neuronal Interact.2006;6(4):355-356.[15] Kedlaya R,Veera S,Horan DJ,et al.Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome.Sci Transl Med.2013;5(211): 158r-211r.[16] Li X,Ominsky MS,Niu QT,et al.Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.J Bone Miner Res.2008;23(6): 860-869.[17] Li X,Ominsky MS,Stolina M,et al.Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. Bone.2009;45(4): 669-676.[18] Ominsky MS,Vlasseros F,Jolette J,et al.Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength.J Bone Miner Res.2010;25(5): 948-959.[19] Shah AD,Shoback D,Lewiecki EM.Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis. Int J Womens Health.2015;7: 565-580.[20] Mcclung MR, Grauer A.Romosozumab in postmenopausal women with osteopenia.N Engl J Med.2014; 370(17): 1664-1665.[21] Saag KG,Petersen J,Brandi ML, et al.Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med.2017;377(15): 1417-1427.[22] 王吉利,万雷,张志海,等.抑制Dickkopf-1和Sclerostin表达对人成骨肉瘤细胞 MG63骨代谢调节相关蛋白表达水平的影响[J].中医正骨,2016,28(9):13-18.[23] Kushwaha P,Khedgikar V,Haldar S,et al.Azadirachta indica triterpenoids promote osteoblast differentiation and mineralization in vitro and in vivo.Bioorg Med Chem Lett. 2016;26(15): 3719-3724.[24] Chapurlat RD,Confavreux CB.Novel biological markers of bone: from bone metabolism to bone physiology. Rheumatology (Oxford).2016;55(10): 1714-1725.[25] Williams BO.LRP5: From bedside to bench to bone.Bone. 2017;102: 26-30.[26] Al-Amer O.Bone marker gene expression in calvarial bones: different bone microenvironments. J Biol Res (Thessalon). 2017;24(12): 9.[27] 王增田,王心,杨静,等.骨桥蛋白影响破骨细胞、成骨细胞参与骨重塑过程的研究进展[J]. 武警后勤学院学报:医学版, 2014(12): 1062-1065.[28] Salehinejad J,Saghafi S,Sharifi N,et al.Evaluation of osteopontin and CD44v6 expression in odontogenic cystic lesions by immunohistochemistry. Pathol Res Pract.2012; 208(7): 410-414.[29] Salamanna F,Pagani S,Maglio M,et al.Estrogen-deficient osteoporosis enhances the recruitment and activity of osteoclasts by breast cancer cells.Histol Histopathol. 2016; 31(1):83-93.[30] Bailey RL,Looker AC,Lu Z,et al.B-vitamin status and bone mineral density and risk of lumbar osteoporosis in older females in the United States. Am J Clin Nutr. 2015;102(3): 687-694.[31] Al-Amer O.Bone marker gene expression in calvarial bones: different bone microenvironments.J Biol Res (Thessalon). 2017;24: 9.[32] 庄洪,魏合伟,林一峰,等.中药骨康含药血清中类雌二醇样物质含量的测定[J].中医正骨,2003,15(11):14-16.[33] 林煜,卢天祥,吴银生,等.健骨颗粒促进成骨细胞增殖的分子机制[J].中国组织工程研究,2013,17(15):2677-2684.[34] 杜武勋,朱明丹,肖学风,等.复方中药药效物质基础研究及其今后应该注意的问题[J].时珍国医国药,2013,24(3):692-694.[35] 李烨,童杰,周衍晶,等.复补肾壮骨中药抗骨质疏松有效成分及其药理作用研究进展[J].中国中药杂志,2015,40(6):1038-1043.[36] 孙宁,邓洋洋,孙鑫,等.补肾、活血复方对骨质疏松症模型大鼠 VEGF 表达的影响[J].中国骨质疏松杂志, 2016,22(9): 1096-1100. |